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Additionally, to effects on bone health, there is mounting 
evidence that Vitamin D plays a vital role in controlling 
inflammation and maintaining balance in the immune 
system.[3] Certain evidence suggests that deficiency in 
Vitamin D results in an imbalance in pulmonary physiology 
INTRODUCTION
The cystic fibrosis (CF) patient population suffers from 
Vitamin D deficiency due to inappropriate absorption 
of fat-soluble vitamins, reduced sunlight contact, and 
decreased intake of Vitamin D-enriched foods.[1] Recent 
literature suggests Vitamin D has a great impact on 
lung function and to combat pulmonary infections.[2] 
Original Article
Background: The function of Vitamin D in preventing inflammation and infection has been studied previously for different 
pathologies in different populations globally. Relationships between serum Vitamin D levels and its effect on pulmonary 
exacerbations in the cystic fibrosis (CF) population are not well studied in our part of the world. Therefore, we aimed to 
ascertain the Vitamin D status in pediatric and adolescent CF patients and its association with pulmonary exacerbations. 
Materials and Methods: A retrospective study was conducted at The Aga Khan University Hospital from 2015 to 2018. 
Patients of CF with sweat chloride value >60 mmol/l and who had at least one measurement of 25 hydroxy Vitamin D (25 
OHD) were included in the study. Annual serum Vitamin D levels were documented for enrolled patients and their past 
1‑year data were analyzed for pulmonary exacerbations, average length of stay, and tracheal/airway colonization with 
organisms. Results: 69 patients were included in the study. 28 patients (40.57%) were found to be Vitamin D deficient, 
22 patients (31.88%) were Vitamin D insufficient and 19 patients (27.53%) were labeled as Vitamin D insufficient. The 
average number of exacerbations per year was significantly high in Vitamin D deficient group (3.71 ± 0.96) in comparison 
with insufficient (3.18 ± 1.09) and sufficient groups (2.26 ± 0.93) (P < 0.001). Conclusion: Vitamin D deficiency is related 
to an increased number of annual pulmonary exacerbations and pseudomonas infections.
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and alters lung architecture.[4] Healthy infants and children 
with a deficiency of Vitamin D have been documented 
to have an increased risk of severe respiratory disease.[5] 
The role of Vitamin D in the CF population is now well 
recognized in literature and its deficiency is associated with 
an increased risk of pulmonary exacerbations.[2] Pulmonary 
functions and the lung’s ability to combat infections are 
important predictors of mortality and morbidity in CF 
patients and Vitamin D status in patients influences these 
predictors.[6,7] Vitamin D deficiency prevalence is elevated 
amongst neonates and children in South Asia.[8] Children 
with CF in South Asia are usually diagnosed late and this 
leads to higher morbidity and mortality.[9]
Serum Vitamin D levels and its effect on pulmonary 
exacerbations are not well documented in our part of the 
world. The objective of our study was to establish the 
Vitamin D status in pediatric CF patients and determine 
its association with pulmonary exacerbations, length of 
stay (LOS) in hospital on average for each exacerbation, 
and bacterial growth in tracheal cultures especially in 
context to Pseudomonas aeruginosa. We hypothesize a 
higher rate of pulmonary exacerbations amongst patients 
with lower Vitamin D status.
MATERIALS AND METHODS
A retrospective study was conducted at The Aga Khan 
University Hospital, Karachi, Pakistan. The study duration 
was from January 2015 to December 2018. We selected 
children and adolescents aged 3–18 years with CF, diagnosed 
based on clinical features and sweat chloride value 
of >60 mmol/L and who had at least one serum measurement 
of 25 hydroxy Vitamin D (25 OHD) levels during the study 
period. Patients were categorized into three groups, Vitamin 
D sufficient, Vitamin D insufficient, and Vitamin D deficient 
groups. CF Patients with serum 25 OHD concentrations < y 
20 ng/ml were labeled as Vitamin D deficient, and those with 
serum 25 OHD concentrations between 20 and 29.9 ng/ml 
were categorized as Vitamin D insufficient, and patient with 
serum 25 OHD concentrations ≥30 ng/ml were labeled as 
Vitamin D sufficient.[2] Annual serum Vitamin D levels were 
documented for every patient and their data for the past 
1 year were analyzed for pulmonary exacerbations, average 
LOS per admission, and colonization of trachea/airway with 
bacteria specifically CF-related organisms like P. aeruginosa 
patients who had CF-related hepatitis or pancreatitis were 
excluded from the study.
Sweat was stimulated by means of pilocarpine iontophoresis 
and sweat collection was done with Wescor® macroduct 
sweat collection system as per hospital protocol. Total 
patients with positive sweat chloride >60 mmol/L 
were analyzed for Delta F-508 genetic mutation. The 
measurement of 25 hydroxy Vitamin D was done in the 
hospital laboratory with a radioimmunoassay kit. These 
data were retrieved from online patient records and 
pharmacy profile.
The fecal elastase test was not available for all patients 
enrolled in the study; therefore, we included all patients 
in our cohort irrespective of their pancreatic sufficiency 
or insufficiency status. Pulmonary exacerbations in 
CF patient was defined as “any hospitalization due to 
respiratory function deterioration clinically observed as 
increased cough frequency, increased sputum production, 
increase work of breathing, and/or new crackles on 
auscultation.”[10] Weight, height, sweat chloride value, 
and Delta F-508 mutation analysis were documented for 
selected cases. Failure to thrive was defined as weight for 
age below −2 SD on Z score. Short stature was defined 
height or length less than two standard deviations for age 
and gender (height for age <−2 Z-score.).
Statistical analysis
Qualitative data were presented as frequencies and 
percentages, whereas quantitative data were presented as 
mean and standard deviation. The normality of the data 
was checked using histograms and Kolmogorov–Smirnov 
test and data were essentially normally distributed. 
One-way ANOVA was used to assess the difference in mean 
values amongst the groups and Chi-square test was used for 
categorical data. The data were analyzed using IBM Corp. 
Released 2011. IBM SPSS Statistics for Windows, Version 
20.0. Armonk, NY: IBM Corp. P < 0.05 was considered 
statistically significant.
RESULTS
A total of 97 CF patients were screened out of which 
69 CF patients fulfilled the eligibility criteria within 
the study duration. Male: female ratio was 1.47:1. 
28 patients (40.57%) were found to be Vitamin D deficient, 
22 patients (31.88%) were labeled as Vitamin D insufficient 
whereas 19 patients (27.53%) were Vitamin D sufficient. 
Frequencies of patients with failure to thrive and short 
stature were similar between the three groups of patients 
and not related to their Vitamin D status. Demographic 
details of CF patients stratified on Vitamin D levels are 
presented in Table 1.
Mean pulmonary exacerbations per year was significantly 
high (3.71 ± 0.96) in Vitamin D deficient groups in 
comparison with insufficient (3.18 ± 1.09) and sufficient 
group (2.26 ± 0.93) P < 0.001. Figure 1 shows the 
comparison of CF patients divided into three groups 
according to the number of exacerbations/years with 
Vitamin D status. Four age categories of patients were 
defined from 3 years to 6 years, 7 years to 10 years, 
11 years to 14 years, and 15 years to18 years. It was 
noticed that the age of the patients had no linear 
relationship with the average number of exacerbations/
year and patients in different age groups showed 
varied frequencies of exacerbations/year Average LOS 
per hospital admission did not show a significant 
difference between the three groups (P = 0.16) [Table 2]. 
The frequency of pseudomonas infections showed a 
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statistically significant difference between the three 
groups (P = 0.043).
DISCUSSION
Our study highlights a significant association between 
the status of Vitamin D in CF patients and pulmonary 
exacerbations. 40.57% of patients were Vitamin D deficient 
and 31.88% patients were Vitamin D insufficient. The 
average number of exacerbations per year was significantly 
high in Vitamin D deficient group (3.71 ± 0.968) 
compared to insufficient and sufficient groups (P < 0.001). 
Average LOS per admission for CF patients showed no 
major differences between the groups (P = 0.16) and 
pseudomonas growth in tracheal swab/sputum cultures 
showed significant differences (P = 0.043).
In our study, CF patients have Vitamin D levels <30 ng/ml. 
Yadav et al. showed that majority of patients in their cohort 
had Vitamin D deficiency with almost all patients who had 
pulmonary exacerbations were deficient in Vitamin D.[9] 
Similarly, Vanstone et al. established depleted Vitamin 
D status as a significant cause of developing pulmonary 
exacerbations.[10] Regardless of patients receiving oral 
supplementation of Vitamin D, the levels remained 
low. Moreover, pulmonary bacterial colonization and 
exacerbations were more prevalent in Vitamin D deficient 
population.[11] 73% of children in our population failed 
to thrive and approximately 60% of children had short 
stature. There was no difference for these features among 
the three categories according to Vitamin D status. This 
indicates that nutritional status may not be an important 
factor in defining Vitamin D statuses in children and 
adolescents with CF.
Pulmonary exacerbations in CF children have a negative 
impact on pulmonary functions resulting in the poor quality 
of life and higher mortality.[12-14] In our study, it is evident 
that the average events of pulmonary exacerbations in the 
group with Vitamin D deficiency were significantly high 
in comparison with Vitamin D insufficient and Vitamin 
D sufficient groups. Our results concur with previously 
published reports, which showed a substantial increase 
in the number of exacerbations in patients with Vitamin 
D deficiency and insufficiency.[2,6,15] Protection from viral 
infections is stated in most studies as a major mechanism 
of Vitamin D in pulmonary protection.[16] There are strong 
data suggesting Vitamin D supplementation during 
inflammation resulting in the reduction of inflammatory 
marker interleukin-8 and improved forced vital capacity, 
suggesting an anti-inflammatory role.[17]
Pseudomonas airway colonization has a great impact on 
lung function, and it is one of the important factors that 
determine the morbidity and mortality in such patients.[18] 
Previously it has been shown that children with Vitamin D 
insufficiency have a higher tendency to be colonized with 
P. aeruginosa. This explains facilitating role of Vitamin D 
in preventing airway infections and long-standing lung 
function in CF.[18] Similarly, studies show that Vitamin D 
plays a role in controlling influential antimicrobial peptide 
Table 1: Demographic details and laboratory features of cystic fibrosis population (n=69)
Vitamin D sufficient Vitamin D insufficient Vitamin D deficient P
Patients,	n	(%) 19	(27.53) 22	(31.88) 28	(40.57)
Age	(months) 10.53±4.53 9.45±4.57 11.51±4.41
Male:	Female 1.50 1.450 1.8
Failure	to	thrive	(weight	for	age−2SD),	n	(%) 13	(68.42) 16	(72.72) 22	(78.57) 0.36
Short	stature	(height	less	than−2SD),	n	(%) 11	(57.89) 13	(59.09) 21	(75) 0.14
Mean	sweat	chloride	value	(mmol/L) 68.07±6.61 77.15±6.92 72.62±6.88 0.69
Delta	F‑508	mutation,	n	(%) 3	(15.78) 4	(18.18) 4	(14.28) 0.53
Mean	serum	25‑OH	Vitamin	D	value	(ng/ml) 52.78±9.63 25.04±3.07 11.11±4.13 <0.05
SD: Standard deviation
Table 2: Average number of exacerbations, length of stay, and pseudomonas infection per year
Vitamin D sufficient (n=19) Vitamin D insufficient (n=22) Vitamin D deficient (n=28) P
Mean	pulmonary	exacerbations/year 2.26±0.93 3.18±1.09 3.71±0.968 <0.001
Average	length	of	stay/admission	(days) 5.92±1.91 6.35±2.04 6.79±2.14 0.16
Pseudomonas	infection,	n	(%) 9	(47.36) 15	(68.18) 23	(82.14) 0.043
Figure 1: Comparison of Vitamin D status and exacerbations/year in 
different age categories
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LL-37. LL-37 has a strong action against P. aeruginosa and it 
was hypothesized that the surplus of bacterial colonization 
predominantly P. aeruginosa in Vitamin-D deficient 
subjects may be the cause of decreased production of 
LL-37, Vitamin D increases levels LL-37 promoting the 
innate immunity.[19] In our study, we found that Vitamin D 
deficient group has an increased number of patients with 
pseudomonas colonization in comparison with insufficient 
and sufficient groups (P = 0.043).
The limitation of our study includes the inability to 
determine the exocrine pancreatic status of the patients 
due to limited excess for all patients for fecal elastase test 
during the study period. Pancreatic enzymes help in the 
absorption of fat-soluble vitamins including Vitamin D and 
have a strong link with the respiratory health and nutrition 
of these patients.[20] We also did not determine pulmonary 
function tests at the time of exacerbations in these patients 
due to the nonavailability of the facility.
CONCLUSION
Our study supports the current recommendation for annual 
screening of fat-soluble vitamin levels especially levels 
of Vitamin D in all patients with CF. Additionally, the 
association between Vitamin D deficiency with pulmonary 
exacerbation and P. aeruginosa colonization deserves 
further prospective design research in order to determine 
more definitively the influence of Vitamin D deficiency on 
inflammation, infection, and clinical outcomes.
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